Several factors likely contribute: the peptide's very short half-life, difficulty crossing the blood-brain barrier in meaningful quantities, small study sizes, differing endpoints (subjective reports versus objective polysomnography), and the placebo-sensitive nature of insomnia outcomes
Plenty of companies are eager to sell insurers, employers and individuals on behavioral alternatives
Mole changes warrant careful monitoring see the Melanotan-2 side effects guide
Metformin was first approved in Canada in 1972, and received subsequent FDA approval in the United States in 1995
Ghareghani M, Dokoohaki S, Ghanbari A et al (2017a) Melatonin exacerbates acute experimental autoimmune encephalomyelitis by enhancing the serum levels of lactate: a potential biomarker of multiple sclerosis progression
In the near term, the most significant challenge facing food and beverage manufacturers is understanding the GLP-1 consumer